Gene · 10644
Papers3,666
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,666
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IGF2BP2 contributes to thyroid cancer progression by enhancing the stability of m6A-modified CTSH mRNA. | PLoS One | 2025 | 41100504 | PubTator, text mining | PubMed |
| The m6A reader IGF2BP2 promotes homologous recombination-mediated DNA repair by eliminating DNA-RNA hybrids. | Cell Rep | 2025 | 41100254 | PubTator, text mining | PubMed |
| RBM15B/IGF2BP2-m6A Mediated Upregulation of FNBP1 Promotes the Progression of Glioblastoma by Promoting Smad3-Mediated Glycolysis. | Drug Dev Res | 2025 | 41086050 | PubTator, text mining | PubMed |
| ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. | iScience | 2025 | 41069850 | PubTator, text mining | PubMed |
| Ouabain-mediated IGF2BP2-GLS/NOS3 axis affects arginine metabolism in diffuse large B-cell lymphoma. | Eur J Med Res | 2025 | 41068864 | PubTator, text mining | PubMed |
| ADAP-METTL3 modulates the inflammatory responses of macrophages via m6A modification of Spry1. | Cell Death Dis | 2025 | 41057319 | PubTator, text mining | PubMed |
| The deubiquitinase USP9X and E3 ligase WWP1 orchestrate IGF2BP2 ubiquitination homeostasis to drive TNBC progression and cisplatin sensitivity. | Cell Death Dis | 2025 | 41053085 | PubTator, text mining | PubMed |
| P4HA2 interacted with ATAD3A to modulate PINK1/parkin-dependent mitophagy and 125I brachytherapy sensitization in esophageal carcinoma. | Cell Death Dis | 2025 | 41053045 | PubTator, text mining | PubMed |
| Single-cell and multi-omics analysis identifies TRIM9 as a key ubiquitination regulator in pancreatic cancer. | Front Immunol | 2025 | 41050689 | PubTator, text mining | PubMed |
| Correction: IGF2BP2 regulates gastric cancer radiotherapy resistance through HIF1α-mediated glycolysis. | Front Oncol | 2025 | 41049836 | PubTator, text mining | PubMed |
| m6A reader IGF2BP2 mediates paclitaxel resistance in esophageal squamous cell carcinoma via FOXM1 mRNA stabilization. | Oncol Rep | 2025 | 41041871 | PubTator, text mining | PubMed |
| Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC. | Theranostics | 2025 | 41041073 | PubTator, text mining | PubMed |
| The Implications of Alternative Splicing Regulation for Maximum Lifespan. | bioRxiv | 2025 | 41040401 | PubTator, text mining | PubMed |
| Direct circMAN1A2(2,3,4,5)-CENPB mRNA interaction regulates cell proliferation and cancer progression. | Nat Commun | 2025 | 41022764 | PubTator, text mining | PubMed |
| Case Report: Insulin resistance in type 1 diabetes mellitus: the role of genetic factors. | Front Endocrinol (Lausanne) | 2025 | 41019343 | PubTator, text mining | PubMed |
| Structural and Functional Studies on Key Epigenetic Regulators in Asthma. | Biomolecules | 2025 | 41008562 | PubTator, text mining | PubMed |
| Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance. | Mol Cancer | 2025 | 40999456 | PubTator, text mining | PubMed |
| Integrative analysis of mRNA, lncRNA, circRNA, and miRNA to investigate the anti-fibrotic activity of silibinin in TGF-β2-treated human trabecular meshwork cells. | BMC Genomics | 2025 | 40999359 | PubTator, text mining | PubMed |
| High-density LD-based structural variations analysis in ten Native and Mestizo Mexican populations. | PLoS One | 2025 | 40997121 | PubTator, text mining | PubMed |
| The m6A modification in cancer: roles, implications, and its potential in therapy. | Mol Biomed | 2025 | 40986143 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10644/papers?page=9